Evidence map›Paper›PMID 38593251›Full record

ReviewPrenatal diagnosis2024

Prenatal cardiac findings and 22q11.2 deletion syndrome: Fetal detection and evaluation.

Elizabeth Goldmuntz, Anne S Bassett, Erik Boot, Bruno Marino, Julie S Moldenhauer, Sólveig Óskarsdóttir, Carolina Putotto, Jack Rychik, Erica Schindewolf, Donna M McDonald-McGinn and 1 more

Open access · hybridAbstract readReview
In one paragraph

Review in Prenatal diagnosis, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 5 countries.

Elizabeth GoldmuntzDivision of Cardiology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
Anne S BassettThe Dalglish Family 22q Clinic, Toronto General Hospital, University Health Network, Toronto, Ontario, Canada.
Erik BootThe Dalglish Family 22q Clinic, Toronto General Hospital, University Health Network, Toronto, Ontario, Canada.
Bruno MarinoDepartment of Maternal Infantile and Urological Sciences, Sapienza University of Rome (Italy), Roma, Italy.
Julie S MoldenhauerDivision of Human Genetics, 22q and You Center, Clinical Genetics Center, Section of Genetic Counseling, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
Sólveig ÓskarsdóttirDepartment of Pediatrics, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Carolina PutottoDepartment of Maternal Infantile and Urological Sciences, Sapienza University of Rome (Italy), Roma, Italy.
Jack RychikDivision of Cardiology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
Erica SchindewolfDivision of Human Genetics, 22q and You Center, Clinical Genetics Center, Section of Genetic Counseling, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
Donna M McDonald-McGinnDepartment of Pediatrics, Perelman School of Medicine of the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Natalie BlagowidowThe Harvey Institute for Human Genetics, Greater Baltimore Medical Center, Baltimore, Maryland, USA.
Children's Hospital of Philadelphia · USSapienza University of Rome · ITUniversity Health Network · CADrottning Silvias barn- och ungdomssjukhus · SEGreater Baltimore Medical Center · US

Funding

Genetic modifiers of congenital heart disease in 22q11.2 deletion syndromeR01HL157157 · NHLBI · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI MORROW, BERNICE E · 2022 to 2025
$3.1M
NHLBI NIH HHS R01 HL157157NIH HHS R01-HL157157-01A1
6 · The paper itself

Abstract

Clinical features of 22q11.2 microdeletion syndrome (22q11.2DS) are highly variable between affected individuals and frequently include a subset of conotruncal and aortic arch anomalies. Many are diagnosed with 22q11.2DS when they present as a fetus, newborn or infant with characteristic cardiac findings and subsequently undergo genetic testing. The presence of an aortic arch anomaly with characteristic intracardiac anomalies increases the likelihood that the patient has 22q11.2 DS, but those with an aortic arch anomaly and normal intracardiac anatomy are also at risk. It is particularly important to identify the fetus at risk for 22q11.2DS in order to prepare the expectant parents and plan postnatal care for optimal outcomes. Fetal anatomy scans now readily identify aortic arch anomalies (aberrant right subclavian artery, right sided aortic arch or double aortic arch) in the three-vessel tracheal view. Given the association of 22q11.2DS with aortic arch anomalies with and without intracardiac defects, this review highlights the importance of recognizing the fetus at risk for 22q11.2 deletion syndrome with an aortic arch anomaly and details current methods for genetic testing. To assist in the prenatal diagnosis of 22q11.2DS, this review summarizes the seminal features of 22q11.2DS, its prenatal presentation and current methods for genetic testing.

Indexed as

DiGeorge SyndromeAorta, ThoracicChromosomes, Human, Pair 22FemaleGenetic TestingHeart Defects, CongenitalHumansPregnancyPrenatal DiagnosisUltrasonography, Prenatal

Identifiers

PMID38593251
PMCPMC11759645
OpenAlexW4394596340

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.